Immunosignaturing microarrays distinguish antibody profiles of related pancreatic diseases

Journal of Proteomics and Bioinformatics

Volumn 6, Issue 7, 2013, Pages

  Kukreja, Muskan ^a   Johnston, Stephen Albert ^a   Stafford, Phillip ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Immune profile; Immunosignature; Microarray proteomics; Pancreas disease; Pancreatic cancer; Pancreatitis; PanIN; Random peptide microarray; Type II diabetes

Indexed keywords

ACUTE PANCREATITIS; ANTIBODY PRODUCTION; ANTIBODY PROFILING; ARTICLE; BLOOD SAMPLING; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOSIGNATURING; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PHENOTYPIC VARIATION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

EID: 84881606847     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.S6-001     Document Type: Article

References (40)

1. Weston AD, Hood L (2004) Systems Biology, Proteomics, and the Future of Health Care:'Äâ Toward Predictive, Preventative, and Personalized Medicine. J Proteome Res 3: 179-196.
2. Ackermann B L, Hale JE, Duffin KL (2006) The Role of Mass Spectrometry in Biomarker Discovery and Measurement. Curr Drug Metab 7: 525-539.
3. Lamont RJ, Meila M, Xia Q, Hackett M (2006) Mass spectrometry-based proteomics and its application to studies of Porphyromonas gingivalis invasion and pathogenicity. Infect Disord Drug Targets 6: 311-325.
4. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, et al. (2005) Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry. Clin Chem 51: 2229-2235.
5. Kiehntopf M, Siegmund R, Deufel T (2007) Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 45: 1435-1449.
6. Chapman K (2002) The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 30: 82-87.
7. Davies HA (2000) The ProteinChip System from Ciphergen: a new technique for rapid, micro-scale protein biology. J Mol Med (Berl) 78: B29.
8. Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ (2005) A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 113: 1669-1674.
9. Diamandis EP, van der Merwe DE (2005) Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 11: 963-965.
10. Elias JE, Haas W, Faherty BK, Gygi SP (2005) Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2: 667-675.
11. Ada GL, Jones PD (1986) The immune response to influenza infection. Curr Top Microbiol Immunol 128: 1-54.
12. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S (2001) Proteomicsbased identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61: 7908-7912.
13. Brydak LB, Machala M (2000) Humoral Immune Response to Influenza Vaccination in Patients from High Risk Groups. Drugs 60: 35-53.
14. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, et al. (1994) An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 12: 993-999.
15. DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, et al. (2002) Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20: 3242-3248.
16. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, et al. (1979) Immune Interferon in the Circulation of Patients with Autoimmune Disease. N Engl J Med 301: 5-8.
17. Lennon VA, Lindstrom JM, Seybold ME (1976) Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci 274: 283-299.
18. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, et al. (2004) Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96: 834-843.
19. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, et al. (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354.
20. Wilder RL (1995) Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 13: 307-338.
21. Boltz KW, Gonzalez-Moa MJ, Stafford P, Johnston SA, Svarovsky SA (2009) Peptide microarrays for carbohydrate recognition. Analyst 134: 650-652.
22. Brown J, Stafford P, Johnston S, Dinu V (2011) Statistical Methods for Analyzing Immunosignatures. BMC Bioinformatics 12: 349.
23. Halperin RF, Stafford P, Johnston SA (2011) Exploring antibody recognition of sequence space through random-sequence peptide microarrays. Mol Cell Proteomics 10: M110.000786.
24. Legutki JB, Magee DM, Stafford P, Johnston SA (2010) A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine 28: 4529-4537.
25. Restrepo L, Stafford P, Magee DM, Johnston SA (2011) Application of immunosignatures to the assessment of Alzheimer's disease. Ann Neurol 70: 286-295.
26. Dugernier TL, Laterre PF, Wittebole X, Roeseler J, Latinne D, et al. (2003) Compartmentalization of the Inflammatory Response during Acute Pancreatitis: Correlation with Local and Systemic Complications. Am J Respir Crit Care Med 168: 148-157.
27. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A (2005) Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 90: 3287-3294.
28. Orchekowski R, Hamelinck D, Li L, Gliwa E, VanBrocklin M, et al. (2005) Antibody Microarray Profiling Reveals Individual and Combined Serum Proteins Associated with Pancreatic Cancer. Cancer Res 65: 11193-11202.
29. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE (2001) Molecular pathology of pancreatic cancer. Cancer J 7: 251-258.
30. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. The Lancet 363: 1049-1057.
31. Saluja AK, Steer ML (1999) Pathophysiology of Pancreatitis. Digestion 60: 27-33.
32. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6: 2969-2972.
33. Katsilambros N, Diakoumopoulou E, Ioannidis I, Liatis S, Makrilakis K, et al. (2006) Pathophysiology of Type 2 Diabetes, in Diabetes in Clinical Practice: John Wiley & Sons, Ltd. 43-58.
34. Ekbom A, McLaughlin JK, Karlsson BM, Nyren O, Gridley G, et al. (1994) Pancreatitis and Pancreatic Cancer: a Population-Based Study. J Natl Cancer Inst 86: 625-627.
35. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92: 2076-2083.
36. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, et al. (1993) Pancreatitis and the Risk of Pancreatic Cancer. N Engl J Med 328: 1433-1437.
37. Deshpande V, Mino-Kenudson M, Brugge W, Lauwers GY (2005) Autoimmune Pancreatitis: More Than Just a Pancreatic Disease?A Contemporary Review of Its Pathology. Arch Pathol Lab Med 129: 1148-1154.
38. Inoue H, Miyatani H, Sawada Y, Yoshida Y (2006) A Case Of Pancreas Cancer With Autoimmune Pancreatitis. Pancreas 33: 208-209.
39. Okazaki K, Chiba T (2002) Autoimmune related pancreatitis. Gut 51: 1-4.
40. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, et al. (2009) The WEKA data mining software: an update. ACM SIGKDD Explor Newsl 11: 10-18.